Investor Alert

New York Markets Open in:



1:41 a.m. Sept. 28, 2021 - By Ciara Linnane
Eli Lilly to reduce list price of Insulin Lispro injection by an additional 40% from Jan. 1, restoring it to 2008 levelsEli Lilly & Co. said Tuesday it is reducing the list price of Insulin Lispro Injection in the U.S. by another 40% effective Jan. 1, 2022, bringing the price down to 2008 levels. "Lilly's Insulin Lispro Injection, 100 units/mL -- first introduced at half the list price of branded Humalog(R) (insulin lispro injection, 100 units/mL) in 2019 -- will now have a 70% lower list price than Humalog U-100," the company said in a statement. People using any of Lilly's insulin products can fill their monthly prescription for $35 through the Lilly Insulin Value Program, for those with commercial insurance or who are uninsured, while seniors can use a program that is part of Medicare Part D plans. "We hope this additional 40 percent cut can expand affordable insulin to more people with diabetes," Lilly Chief Executive David Ricks said in a statement. Lilly shares were down 0.4% premarket.
2:00 a.m. July 14, 2021 - By Ciara Linnane
Eli Lilly buys remaining shares of Protomer Technologies in glucose-responsive insulin playEli Lilly & Co. said Wednesday it is acquiring the shares of Protomer Technologies it does not already own, in a deal it says has a potential value of more than $1 billion based on future development and commercial milestones. Lilly had previously purchased a 14% stake in the company, which has a proprietary peptide- and protein-engineering platform that can be used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity. Protomer was founded in 2015 in Pasadena, California. "Protomer has used this approach toward advancing a portfolio of therapeutic candidates, including glucose-responsive insulins that can sense sugar levels in the blood and automatically activate as needed throughout the day," Lilly said in a statement. Lilly said the deal will not impact its 2021 non-GAAP EPS. Lilly shares were not yet active premarket, but have gained 39% in the year to date, while the S&P 500 has gained 16%.
Browse topics:
Link to MarketWatch's Slice.